Toggle Main Menu Toggle Search

Open Access padlockePrints

Rituximab and abatacept for rheumatoid arthritis

Lookup NU author(s): Professor John IsaacsORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Estimates from the UK indicate that around 0.5-1.0% of the population have rheumatoid arthritis. Here we assess the place of rituximab (MabThera--Roche Products Ltd) and abatacept (Orencia--Bristol-Myers-Squibb), drugs in two new classes, which are licensed for certain adults with the condition.

Publication metadata

Author(s): Isaacs JD

Publication type: Article

Publication status: Published

Journal: Drug and Therapeutics Bulletin

Year: 2008

Volume: 46

Issue: 8

Pages: 57-61

Print publication date: 01/08/2008

ISSN (print): 0012-6543

ISSN (electronic): 1755-5248

Publisher: BMJ Group


DOI: 10.1136/dtb.2008.07.0017

Notes: BMJ Group Journal Article England


Altmetrics provided by Altmetric